TOKYO and TEANECK, NJ--(MARKET WIRE)--Jul 12, 2006 -- Eisai Co., Ltd. and Eisai Inc. jointly announce today that the companies and Teva Pharmaceutical Industries Ltd. mutually agreed to end a collaboration agreement for rasagiline, which was established in May 2003. Eisai Co., Ltd. is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd. The company focuses its efforts in three therapeutic areas -- neurology, gastrointestinal disorders and oncology/critical care -- and currently has several proprietary and promising compounds in development in these specialties.
Contact: Contacts: Corporate Communications Department Eisai Co., Ltd. 011-81-3-3817-5120
Cathy Pollini Eisai Inc. 201-287-2052
Source: Eisai Co., Ltd. and Eisai Inc.
